Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters
© Rideout et al.; licensee BioMed Central Ltd. 2014
Received: 19 November 2013
Accepted: 13 December 2013
Published: 6 January 2014
Skip to main content
We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
© Rideout et al.; licensee BioMed Central Ltd. 2014
Received: 19 November 2013
Accepted: 13 December 2013
Published: 6 January 2014
In addition to lowering LDL-C, emerging data suggests that phytosterols (PS) may reduce blood triglycerides (TG), however, the underlying mechanisms are not known.
We examined the TG-lowering mechanisms of dietary PS in Syrian golden hamsters randomly assigned to a high fat (HF) diet or the HF diet supplemented with PS (2%) for 6 weeks (n = 12/group). An additional subset of animals (n = 12) was provided the HF diet supplemented with ezetimibe (EZ, 0.002%) as a positive control as it is a cholesterol-lowering agent with known TG-lowering properties.
In confirmation of diet formulation and compound delivery, both the PS and EZ treatments lowered (p < 0.05) intestinal cholesterol absorption (24 and 31%, respectively), blood non-HDL cholesterol (61 and 66%, respectively), and hepatic cholesterol (45 and 55%, respectively) compared with the HF-fed animals. Blood TG concentrations were lower (p < 0.05) in the PS (49%) and EZ (68%)-treated animals compared with the HF group. The TG-lowering response in the PS-supplemented group was associated with reduced (p < 0.05) intestinal SREBP1c mRNA (0.45 fold of HF), hepatic PPARα mRNA (0.73 fold of HF), hepatic FAS protein abundance (0.68 fold of HD), and de novo lipogenesis (44%) compared with the HF group. Similarly, lipogenesis was lower in the EZ-treated animals, albeit through a reduction in the hepatic protein abundance of ACC (0.47 fold of HF).
Study results suggest that dietary PS are protective against diet-induced hypertriglyceridemia, likely through multiple mechanisms that involve modulation of intestinal fatty acid metabolism and a reduction in hepatic lipogenesis.
Although LDL-C levels have decreased among US adults in recent years largely due to the widespread and effective use of lipid lowering medication, hypertriglyceridemia is increasingly prevalent with 33.1% of Americans having borderline high triglyceride (TG) levels . This mean increase in TG concentrations amongst men and women over the past 20 years has coincided with the alarming obesity trend and is further associated with increased risk of acute pancreatitis and cardiovascular disease (CVD) . Data from the National Health and Nutrition Examination Survey (NHANES) suggests that > 80% of overweight (BMI 25–30 kg/m2) and obese (BMI ≥30 kg/m2) subjects have TG concentrations ≥1.69 mmol/L .
Moderate hypertriglyceridemia (1.69-2.24 mmol/L) is treated with body weight reduction through lifestyle modifications of diet and physical activity while severe cases (>5.6 mmol/L) require first-line drug therapy with a range of pharmaceuticals including statins, fibrates, niacin, and prescription n-3 fatty acids . Marine-derived n-3 fatty acids are considered the most effective nutraceutical TG-lowering option (~30%), however, phytosterols (PS) have recently been explored for their potential TG-lowering effects beyond their established LDL-C lowering efficacy. Although the majority of clinical PS intervention studies have failed to observe significant TG lowering responses, two studies specifically designed to examine the TG-lowering potential of PS reported reductions in the range of 11-27%, depending on baseline TG concentration [5, 6]. The precise mechanism (s) responsible for the TG-lowering effects of PS are not known, however, we recently observed an increase in fecal saturated fatty acid excretion in C57Bl6 mice fed a PS-enriched diet, suggesting a possible interference with intestinal fat absorption . Furthermore, although previous work suggests that PS may be effective in reducing TG in subjects with established, overt hypertriglyceridemia, it is unknown if PS provides protection against diet-induced increases in TG following high fat feeding. Considering the effectiveness of PS in reducing LDL-C by interfering with intestinal cholesterol absorption, knowledge of the TG-lowering potential of PS and the underlying mechanisms involved will be critical in ascertaining the utility of PS as a potential therapy against mixed dyslipidemia. Therefore, the objective of this study was to examine the effectiveness of PS in protecting against diet-induced hypertriglyceridemia in Syrian golden hamsters fed a high fat TG-raising diet. We utilized EZ as a comparative control as it is another well-characterized cholesterol-absorptive inhibitor that is recognized to reduce circulating TG concentrations in humans and a previous study using the Syrian golden hamster .
Establishment of high fat feeding model on body weight and blood lipid parameters in Syrian golden hamsters 2
Whole body parameters
Initial body weight (g)
124.13 ± 1.81
126.21 ± 1.81
Final body weight (g)
139.58 ± 3.27
151.18 ± 3.42*
Body weight change (%)
15.18 ± 2.64
25.75 ± 2.75*
Total cholesterol (mmol/L)
4.65 ± 0.31
6.45 ± 0.31*
Non-HDL cholesterol (mmol/L)
2.19 ± 0.21
2.87 ± 0.21*
2.45 ± 0.21
3.57 ± 0.21*
2.48 ± 0.46
5.26 ± 0.46*
10.76 ± 0.66
12.16 ± 0.87*
90.18 ± 11.92
86.20 ± 8.90
62.0 ± 8.24
83.60 ± 8.32*
Findings from this study suggest that dietary PS, in addition to their established cholesterol-lowering properties, may also protect against diet-induced hypertriglyceridemia. This TG-lowering response appears to be due to modulation of fat metabolism in the intestine and the liver as evidenced by a reduction in intestinal SREBP1c and PPARα mRNA expression and a decrease in hepatic FAS protein abundance and de novo lipogenesis. These results would seem to confirm the limited animal [9, 10] and human data [5, 11] that suggests a TG-lowering response to PS supplementation and suggest that PS may be effective in protecting against diet-induced mixed dyslipidemia.
In this diet-induced hypertriglyceridemic hamster model, blood and tissue lipid responses to PS supplementation were comparable to those observed with EZ, a suitable positive control as it has a similar cholesterol-lowering effect to PS but also possesses a more well-characterized effect on TG metabolism including reductions in blood TG [12–15] and amelioration of hepatic TG accumulation  and steatosis [17, 18]. As a confirmation of both the diet composition and experimental protocol, both PS and EZ-treated animals demonstrated an expected inhibition of intestinal cholesterol absorption and a reduction in blood total and non-HDL-C cholesterol below that of the LF-fed animals. Although it is not completely understood how a cholesterol-absorptive inhibitor could modulate TG metabolism, a few recent reports have examined the issue specifically with EZ.
Naples et al. (2012) suggested that EZ may lower postprandial TG by modulating intestinal fatty acid absorption and chylomicron assembly by reducing apoB48 production and modulating the expression of intestinal lipid synthesis and transport genes in fructose and fat-fed hamsters . Similarly, we observed a reduction in intestinal SREBP1c mRNA in both the EZ and PS groups, thus confirming the previous report by Naples et al. (2012) and further suggesting that PS may reduce blood TG through a similar intestinal SREBP1c-related mechanism. It is not known why we did not observe a corresponding reduction in the cytoplasmic or nuclear protein abundance of SREBP1c in the PS and EZ groups. We previously reported a reduction in intestinal PPARα mRNA expression and increased fecal FA loss in C57BL/6 J mice fed a PS supplemented diet . Taken together, it appears that at least part of the TG-lowering effects of PS is associated with the modulation of multiple intestinal FA regulatory targets.
With the knowledge that excessive hepatic cholesterol is lipogenic through the activation of the liver X-receptor (LXR) [20, 21], a more direct link between the cholesterol-lowering properties of EZ and TG-reductions has been proposed. In a HF-fed hamster model, Ushio et al. (2013) reported that in response to a limitation in intestinal cholesterol absorption, EZ reduced hepatic oxysterol LXRα ligands, thus inhibiting LXRα-induced transcriptional stimulation of SREBP-1c . However, after failing to observe a reduction in SREBP1c lipogenic targets in the EZ-treated animals, the authors concluded that EZ did not likely reduce hepatic lipogenesis through this pathway. Contrary to this conclusion, our results suggest that EZ reduces ACC protein abundance and inhibits hepatic de novo lipogenesis. Our results further suggest that PS supplementation may modulate hepatic fat metabolism through a similar reduction in hepatic lipogenesis, albeit through a reduction in the protein abundance of FAS. Further work is required to determine if this reduction in hepatic lipogenesis in PS-supplemented animals is directly related to the observed reduction in hepatic cholesterol concentration and an associated inhibitory effect on the LXRα-SREBP1c lipogenic stimulus pathway. The observed reduction in hepatic lipogenesis in PS-supplemented hamsters is in direct contrast to our previous report of increased lipogenesis in C57BL/6 J PS-supplemented mice . Given the similarity in the design factors between the two studies, including diet, feeding protocol and stable isotope analysis, this discrepancy highlights the underlying differences in lipid metabolism amongst rodent species and cautions against premature translation of biological efficacy and mechanistic data regarding potential disease treatment strategies from animal models .
Although hepatic fatty acid profile is a major determinant of de novo lipogenesis, this does not appear to be a contributing factor to explain the reduced fatty acid synthesis observed in the PS and EZ treated animals. Both fatty acid chain length and degree of unsaturation affect lipogenic gene expression, with monounsaturated fatty acids (MUFA) and longer-chain polyunsaturated fatty acids (PUFA) having a general inhibition and saturated fatty acids (SFA) having a stimulatory effect in parallel with fatty acid elongation pathways . As both PS and EZ both shifted the hepatic FA profile towards an increase in palmitate (~50%) and a reduction in oleic acid (~24%), it appears that modulation of hepatic fatty acid distribution was not a determinant in the observed reduction in lipogenesis observed in these groups. Although little work has examined hepatic FA concentration in response to PS, our results are supported by a previous report by Brufau et al. (2006) suggesting an increase in the hepatic SFA fraction in guinea pigs supplemented with PS .
Intracellular hepatic fatty acids also serve as lipid signaling molecules by inducing PPARα activation. In this way, PPARα is thought to protect against fat accumulation by enhancing expression of rate-limiting enzymes in the β-oxidation pathway. Previous work suggests that a wide spectrum of fatty acids are capable of transactivating PPARα and inducing DNA binding activity, particular long chain PUFA . However, as we observed no change in hepatic total fatty acids and a reduction in 18:2 in the PS-supplemented group, the underlying mechanisms and physiological implication of reduced PPARα abundance is unclear.
Although inclusion of EZ as a comparative control to examine the TG-lowering mechanisms of PS may be considered a study strength, direct comparison of the lipid-lowering magnitude between the PS and EZ groups may not be appropriate given that the dietary inclusion levels, although similar to those typically used in previous animal studies, exceeds normal PS intakes (2 g/d) and EZ prescribed doses (~10 mg/d) in humans. Although the cholesterol-lowering response to PS (~10%) and EZ (~20%) are fairly consistent, the magnitude of TG lowering is considerably more variable for both PS (6-15%) and EZ (10-20%) and likely dependent on baseline TG concentrations [11, 26–28].
Here, we demonstrate that PS supplementation offers protection against diet-induced hypertriglyceridemia in Syrian golden hamsters fed a high fat diet. Our data suggest that several mechanisms, namely reductions in dietary fat absorption, intestinal SREBP1c mRNA expression, hepatic PPARα abundance, and de novo lipogenesis may be contributing to the reduction in circulating TG. Clarification of the mechanisms underlying these TG reductions may broaden the clinical utility of PS supplementation beyond LDL-C lowering to a potential therapy for mixed dyslipidemias.
Formulation of experimental diets (%) for Syrian golden hamsters
AIN76-A mineral mix
AIN76-A vitamin mix
Following the 6-week feeding period, hamsters were anesthetized with isoflurane for blood and tissue collection then killed by exsanguination while in the surgical plane of anesthesia. Fasting (8 hrs) blood (serum and EDTA plasma) was collected by cardiac puncture and processed as previously described . The liver and proximal small intestine were quickly excised, rinsed/flushed in chilled saline (pH 7.4, 154 mM containing 0.1 mM phenylmethylsulfonyl fluoride) and flash frozen in liquid nitrogen. All tissues were stored at −80°C until further processing and analyses.
Plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), and TG were determined by automated enzymatic methods on a Vitros 350 chemistry analyzer (Ortho-Clinical Diagnostics, Markham, Ontario, Canada). Non-HDL-C was calculated by difference.
Serum free cholesterol and cholesteryl esters were measured by high performance liquid chromatography (HPLC) according to our modification of Vercaemst et al. . Briefly, one volume of serum was diluted with five volumes of isopropanol containing cholesteryl heptadecanoate as the internal standard. Samples were vortexed for 30 minutes, centrifuged, and injected (50 uL) onto a 25 cm × 4.6 mm reverse phase column using an isocratic mobile phase of acetonitrile/isopropanol (60:40 v/v) at a flow rate of 2.0 mL/min and 45°C. Unesterified cholesterol and cholesteryl esters [palmitate (CE-16:0), oleate (CE-18:1), linoleate (CE-18:2), and arachidonate (CE-20:4)] were detected by their UV absorbance at 208 nm and quantified in comparison to pure standards after correcting for internal standard recovery.
Red blood cell PS concentrations were determined by gas–liquid chromatography according to previously established procedures  using a gas chromatography (6890 GC, Agilent Technologies, Palo Alto, California) equipped with flame ionization detector and auto-injector system. A 30-m SAC-5 column (Sigma-Aldrich Canada Ltd., Oakville, Ont.) was used. Briefly, 5-α cholestane as an internal standard was added to each of the samples followed by addition of methanolic potassium hydroxide and saponification. Sterols were extracted from the mixture with petroleum ether. Extracted samples were derivatized with TMS reagent (pyridine-hexamethyldisilazan-trimethylchlorosilane (9:3:1, v/v)) and samples were injected into the GC. The injector and detector were set at 300 and 310 degrees C, respectively. The flow rate of the carrier gas, helium was 1.2 ml/min with the inlet splitter set at 100:1. Individual PS were identified using authentic standards (Sigma-Aldrich Canada Ltd., Oakville, Ont). Internal standards were used to calculate detector response factors. Campesterol and β-sitosterol concentrations were determined by identifying the peak sizes and expressing them relative to 5-α cholestane internal standard.
Hepatic cholesterol was extracted and analyzed according to our previously published procedures [7, 32]. Approximately 500 mg of pulverized liver was spiked with α-cholestane as internal standard and saponified in freshly prepared KOH–methanol at 100°C for 1 h. The non-saponifiable sterol fraction was extracted with petroleum diethyl ether and dried under N2 gas. For analysis of hepatic fatty acids, approximately 0 · 5 g of pulverized liver was spiked with heptadecanoic acid (C17:0) as internal standard. Total lipids were isolated from liver tissue with a modified Dole mixture (3 hepatane:12 propanol:3 DDH2O, vol:vol) followed by extraction with heptane: DDH2O (3:1 vol:vol) . Fatty acid extracts were methylated with methanolic boron trifluoride (Sigma Aldrich, St. Louis, MO).
Sterol and fatty acid fractions were analyzed using a Shimadzu GC-17A gas chromatograph fitted with a flame ionization detector. A SAC-5 capillary column (30 m × 0 · 25 mm × 0 · 25 mm, Supelco, Bellefonte, CA, USA) was used for cholesterol analyses. Fatty acid methyl esters were separated using a Supelcowax 10 column (30 m × 0 · 25 mm with 0 · 25 m film thickness; Supelco, Bellefonte, PA, USA). Relative hepatic fatty acid content was calculated by using individual FA peak area relative to the total area and expressed as the percentage of total fatty acids.
Total RNA was isolated from whole intestinal tissue using TRIzol reagent (Invitrogen Canada Inc., Burlington, ON). RNA concentration and integrity was determined with spectrophotometry (260 nm) and agarose gel electrophoresis, respectively. RNA preparation and real-time RT-PCR was conducted using a one-step QuantiTect SYBR Green RT-PCR kit (Qiagen Inc., Mississauga, ON, Canada) on a Biorad MyiQ real time PCR system according to previously established protocols . Sequences of sense and antisense primers for target and housekeeping genes were based on previously published reports for NPC1L1 , CD36, FABP2 , SREBP1c, , and β-actin .
Immunoblots were prepared as previously described . Nuclear and cytoplasmic extracts for immunoblot analyses of peroxisome proliferator-activated receptor alpha (PPARα, SC-9000, Santa Cruz Biotechnology), SREBP1c (Novus Biologicals, NB600-582), fatty acid synthase (FAS, C2OG5, Cell Signaling), and acetyl-CoA carboxylase (ACC, C83B10, Cell Signaling), were separated using the CelLytic™ NuCLEAR™ extraction kit (Sigma, Saint Louis, Missouri, USA). Intestinal apical membrane extracts were extracted according to a previously established protocol probed for NPC1L1 (Santa Cruz, sc-67237) . Target proteins were normalized to β-actin and quantified using Image J (National Institutes of Health, Bethesda, Maryland).
Where ΔTGFA is the change in deuterium enrichment in hepatic-palmitate; Δplasma is the change in the deuterium enrichment of the precursor plasma water; and 0.477 is derived from 0.87 g-atom 3H per g-atom carbon incorporated into adipose tissue fatty acids and a correction factor to account for the glycerol moiety as previously described . Lipogenesis rates are expressed relative to the HF group.
Forty-eight hours prior to euthanization, hamsters were given an oral gavage of safflower oil containing 5 mg of [3,4]-13C cholesterol (99% enriched; CDN Isotopes). As an indicator of cholesterol absorption, GC-combustion-isotope ratio MS (Delta V Plus, Thermo Scientific) was used to determine the 13C enrichment (13C/12C ratio) of free cholesterol in RBC compared with the non-enriched hamster RBC 13C-cholesterol enrichment over 48 h .
Data were analyzed with a general linear model ANOVA using experimental block as a fixed factor . To establish the effect of HF-feeding, responses between the LF versus the HF groups were compared using a paired t-test. Multiple comparisons between treatment groups were analyzed with Tukey’s post-hoc test. Data were analyzed with SPSS 16 for Mac (SPSS Inc, Chicago IL). Data are presented as mean ± SEM. All results are the means from 12 animals unless otherwise stated. Differences were considered significant at p ≤ 0.05.
The technical assistance of Amy Raslawsky and Marie-Lou Bodziac is greatly appreciated.
Funded by the Natural Sciences and Engineering Research Council of Canada (to PJ) and a KO1 grant from the National Institute for Complementary and Alternative Medicine (to TCR).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.